JP4822562B2 - 低ヘモグロビン濃度細胞百分率および鉄欠乏の検出における使用方法 - Google Patents
低ヘモグロビン濃度細胞百分率および鉄欠乏の検出における使用方法 Download PDFInfo
- Publication number
- JP4822562B2 JP4822562B2 JP2008551542A JP2008551542A JP4822562B2 JP 4822562 B2 JP4822562 B2 JP 4822562B2 JP 2008551542 A JP2008551542 A JP 2008551542A JP 2008551542 A JP2008551542 A JP 2008551542A JP 4822562 B2 JP4822562 B2 JP 4822562B2
- Authority
- JP
- Japan
- Prior art keywords
- lhcc
- mchc
- blood
- iron deficiency
- hemoglobin concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010022971 Iron Deficiencies Diseases 0.000 title claims description 81
- 108010054147 Hemoglobins Proteins 0.000 title claims description 69
- 102000001554 Hemoglobins Human genes 0.000 title claims description 69
- 238000000034 method Methods 0.000 title claims description 37
- 210000003743 erythrocyte Anatomy 0.000 claims description 102
- 210000004369 blood Anatomy 0.000 claims description 96
- 239000008280 blood Substances 0.000 claims description 96
- 210000004027 cell Anatomy 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 239000003085 diluting agent Substances 0.000 claims description 11
- 230000002596 correlated effect Effects 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 66
- 239000000523 sample Substances 0.000 description 61
- 229910052742 iron Inorganic materials 0.000 description 33
- 238000009826 distribution Methods 0.000 description 22
- 230000006870 function Effects 0.000 description 21
- 238000005259 measurement Methods 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 15
- 208000007502 anemia Diseases 0.000 description 12
- 230000002950 deficient Effects 0.000 description 12
- 235000020796 iron status Nutrition 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 9
- 210000001995 reticulocyte Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 102000008857 Ferritin Human genes 0.000 description 7
- 108050000784 Ferritin Proteins 0.000 description 7
- 238000008416 Ferritin Methods 0.000 description 7
- 102000004338 Transferrin Human genes 0.000 description 7
- 108090000901 Transferrin Proteins 0.000 description 7
- 230000010437 erythropoiesis Effects 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000012581 transferrin Substances 0.000 description 7
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000003339 best practice Methods 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 2
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 238000002847 impedance measurement Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 206010050789 Hypochromasia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali metal salts Chemical class 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
本願は、2006年1月20日に出願された米国仮特許出願第60/760,520号の、米国特許法第119(e)条の下での利益を主張する。米国仮特許出願第60/760,520号は、その全体が本明細書中に参考として援用される。
本発明は、新しい診断パラメーターである低ヘモグロビン濃度細胞百分率を生成する方法、および鉄欠乏の検出において使用されるその方法に関する。
鉄欠乏(ID)は、世界中各地で最もよく見られる単一欠乏状態である。鉄欠乏により、罹患者は肉体労働を行うことができなくなり、また、小児における成長および学習の両方が損なわれるので、鉄欠乏は経済的に重要である。
Thomasら、Biochemical Markers and Hematologic Indices in the Diagnosis of Functional Iron Deficiency、Clinical Chemistry、第48巻、7号、1066〜1076頁、2002年 Revised European Best Practice Guidelines for the Management of Anaemia in Patients With Chronic Renal Failure、Locatelli, F.ら、Nephrology and Dyalisis Transplantation、第19巻、2004年5月(増刊第2号)、ガイドラインIII.2、ii22〜24頁 Revised European Best Practice Guidelines for the Management of Anaemia in Patients With Chronic Renal Failure、Locatelli, F.ら、Nephrology and Dyalisis Transplantation、第19巻、2004年5月(増刊第2号)、付録B、ii39〜41頁 Machin S.J.ら、Functional Iron Deficiency and New Red Cell Parameters on the Sysmex XE−2100、ISLH 2001 Industry−Sponsored Workshops, ISLH XIVth International Symposium、2001年 Thomas, C.ら、Anemia of Chronic Disease: Pathophysiology and Laboratory Diagnosis, Laboratory Hematology、2005年、11号、14〜23頁
1つの実施形態において、本発明は、低ヘモグロビン濃度細胞百分率(LHCC%)を血液分析装置で生成する方法に関する。この方法は、血液サンプルの第1のアリコートを血液希釈剤と混合して、第1のサンプル混合物を形成し、第1のサンプル混合物を血液分析装置で分析し、赤血球の平均赤血球容積(MCV)および赤血球濃度(RBC)を得ること;血液サンプルの第2のアリコートを試薬系と混合して、第2のサンプル混合物を形成し、第2のサンプル混合物を血液分析装置で分析し、血液サンプルのヘモグロビン濃度(Hgb)を得ること;得られたMCV、RBCおよびHgbを使用して平均赤血球ヘモグロビン濃度(MCHC)を得ること;得られたMCHCを使用して低ヘモグロビン濃度細胞百分率(LHCC%)を得ること;および血液サンプルのLHCC%を血液分析装置で報告することを含む。
本発明は、新しい診断パラメーターである低ヘモグロビン濃度細胞百分率(LHCC%)、および鉄欠乏の検出のために使用される方法を提供する。
LHCC%=1/(1+(EXP(d*(q−MCHC))))*100
(式中、dおよびqは定数である)
によって定義される平均赤血球ヘモグロビン濃度(MCHC)のシグモイド関数である。1つの例示的な実施形態において、dおよびqがそれぞれ1.8および30である。
強調LHCC%=SQRT((1−(1/(1+(EXP(d*(q−MCHC)))))))*100
(式中、dおよびqは定数である)
によって定義される強調LHCC%を提供する。1つの例示的な実施形態において、dおよびqがそれぞれ1.8および30である。
Claims (14)
- 血液サンプルの低ヘモグロビン濃度細胞百分率(LHCC%)を血液分析装置で生成する方法であって、
(a)血液サンプルの第1のアリコートを血液希釈剤と混合して、第1のサンプル混合物を形成し、前記第1のサンプル混合物を前記血液分析装置で分析し、赤血球の平均赤血球容積(MCV)および赤血球濃度(RBC)を得ること;
(b)前記血液サンプルの第2のアリコートを試薬系と混合して、第2のサンプル混合物を形成し、前記第2のサンプル混合物を前記血液分析装置で分析し、前記血液サンプルのヘモグロビン濃度(Hgb)を得ること;
(c)前記MCV、前記RBCおよび前記Hgbを使用して平均赤血球ヘモグロビン濃度(MCHC)を得ること;
(d)前記MCHCの関数として前記低ヘモグロビン濃度細胞百分率(LHCC%)を得ること;および
(e)前記血液サンプルの前記LHCC%を前記血液分析装置で報告すること
を含む方法。 - 前記LHCC%が前記MCHCのシグモイド関数である、請求項1に記載の方法。
- 前記LHCC%が、下記の式:
LHCC%=1/(1+(EXP(d*(q−MCHC))))*100
(式中、dおよびqは定数である)
によって定義される、請求項1に記載の方法。 - 前記dおよびqがそれぞれ1.8および30である、請求項3に記載の方法。
- 前記LHCC%が、下記の式:
強調LHCC%=SQRT((1−(1/(1+(EXP(d*(q−MCHC)))))))*100
(式中、dおよびqは定数である)
によって定義される強調LHCC%である、請求項1に記載の方法。 - 前記dおよびqがそれぞれ1.8および30である、請求項5に記載の方法。
- 前記低ヘモグロビン濃度細胞百分率(LHCC%)が低色素性赤血球百分率と線形相関する、請求項1に記載の方法。
- 前記低ヘモグロビン濃度細胞百分率(LHCC%)が前記MCHCの非線形リスケーリングによって得られる、請求項1に記載の方法。
- 鉄欠乏を検出する方法であって、
(a)血液サンプルを血液分析装置で分析し、赤血球の平均赤血球ヘモグロビン濃度(MCHC)を得る工程;
(b)前記MCHCの関数として低ヘモグロビン濃度細胞百分率(LHCC%)を得る工程;
(c)前記LHCC%を所定の鉄欠乏基準と比較する工程;および
(d)前記LHCC%が前記所定の鉄欠乏基準を満たす場合に、鉄欠乏を示すことを報告する工程
を含む方法。 - 前記LHCC%が前記MCHCのシグモイド関数である、請求項9に記載の方法。
- 前記LHCC%が、下記の式:
LHCC%=1/(1+(EXP(d*(q−MCHC))))*100
(式中、dおよびqは定数である)
によって定義される、請求項9に記載の方法。 - 前記dおよびqがそれぞれ1.8および30である、請求項11に記載の方法。
- 前記LHCC%が、下記の式:
強調LHCC%=SQRT((1−(1/(1+(EXP(d*(q−MCHC)))))))*100
(式中、dおよびqは定数である)
によって定義される強調LHCC%である、請求項9に記載の方法。 - 前記dおよびqがそれぞれ1.8および30である、請求項13に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76052006P | 2006-01-20 | 2006-01-20 | |
US60/760,520 | 2006-01-20 | ||
PCT/US2007/060753 WO2007084977A2 (en) | 2006-01-20 | 2007-01-19 | Low hemoglobin concentration cell percentage and method of use in detection of iron deficiency |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009524069A JP2009524069A (ja) | 2009-06-25 |
JP4822562B2 true JP4822562B2 (ja) | 2011-11-24 |
Family
ID=38288401
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008551541A Active JP4925364B2 (ja) | 2006-01-20 | 2007-01-19 | 鉄欠乏を検出する方法 |
JP2008551542A Expired - Fee Related JP4822562B2 (ja) | 2006-01-20 | 2007-01-19 | 低ヘモグロビン濃度細胞百分率および鉄欠乏の検出における使用方法 |
JP2011262741A Expired - Fee Related JP5592339B2 (ja) | 2006-01-20 | 2011-11-30 | 鉄欠乏を検出する方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008551541A Active JP4925364B2 (ja) | 2006-01-20 | 2007-01-19 | 鉄欠乏を検出する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011262741A Expired - Fee Related JP5592339B2 (ja) | 2006-01-20 | 2011-11-30 | 鉄欠乏を検出する方法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US7361512B2 (ja) |
EP (2) | EP2016423B1 (ja) |
JP (3) | JP4925364B2 (ja) |
WO (2) | WO2007084977A2 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2332977B1 (en) | 2004-07-23 | 2015-11-25 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
DK1973559T3 (da) | 2005-11-23 | 2013-03-25 | Acceleron Pharma Inc | Activin-ActRIIa antagonister samt anvendelser til fremme af knoglevækst |
EP2016423B1 (en) * | 2006-01-20 | 2011-07-13 | Beckman Coulter, Inc. | Methods of detection of iron deficiency |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
CN104524548A (zh) * | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
CN103920139B (zh) * | 2007-02-01 | 2018-02-02 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
TWI459963B (zh) | 2007-02-09 | 2014-11-11 | Acceleron Pharma Inc | 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途 |
CN107412734A (zh) * | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
KR20190128002A (ko) * | 2008-06-26 | 2019-11-13 | 악셀레론 파마 인코포레이티드 | 액티빈-actriia 길항물질을 투약하는 방법 및 치료된 환자의 모니터링 |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
TWI626945B (zh) * | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
WO2010054180A1 (en) * | 2008-11-07 | 2010-05-14 | Beckman Coulter, Inc. | High sensitivity parameters for the detection of vitamin b12 and/or folate deficiencies and methods of use |
AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
EP2425241A4 (en) | 2009-04-27 | 2015-05-13 | Abbott Lab | METHOD FOR THE DISTINCTION OF RED BLOOD CELLS OF WHITE BLOOD CELLS BY FORWARD SCREENING FROM A LASER IN AN AUTOMATED HEMATOLOGICAL ANALYZER |
EP2440576A4 (en) * | 2009-06-08 | 2013-11-20 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES |
KR20210034684A (ko) | 2009-06-12 | 2021-03-30 | 악셀레론 파마 인코포레이티드 | 절두된 ActRIIB-FC 융합 단백질 |
KR20120062874A (ko) * | 2009-09-09 | 2012-06-14 | 악셀레론 파마 인코포레이티드 | ActRIIb 길항제들와 이의 투약 및 용도 |
US20110129469A1 (en) * | 2009-11-03 | 2011-06-02 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
EP2501400B1 (en) | 2009-11-17 | 2017-11-01 | Acceleron Pharma, Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
US8906308B2 (en) | 2010-01-15 | 2014-12-09 | Abbott Laboratories | Method for determining volume and hemoglobin content of individual red blood cells |
EP2594607B1 (en) * | 2010-07-16 | 2019-03-20 | Sumitomo Chemical Company Limited | Composition containing polymer compound and light-emitting element using same |
US9938557B2 (en) | 2010-09-16 | 2018-04-10 | The General Hospital Corporation | Red blood cell dynamics for administering treatment for iron-deficiency anemia |
JP2014502260A (ja) | 2010-11-08 | 2014-01-30 | アクセルロン ファーマ, インコーポレイテッド | Actriia結合剤およびその使用 |
CN103827658B (zh) | 2011-07-22 | 2016-04-13 | 罗氏血液诊断股份有限公司 | 识别和测量网状细胞 |
KR102279522B1 (ko) | 2012-11-02 | 2021-07-19 | 셀진 코포레이션 | 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도 |
US20170108487A1 (en) * | 2014-06-05 | 2017-04-20 | The General Hospital Corporation | Predicting morbidity associated with red blood cell volume variance |
EP3154566B1 (en) | 2014-06-13 | 2022-08-03 | Acceleron Pharma Inc. | Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
HUE062189T2 (hu) | 2014-12-03 | 2023-09-28 | Celgene Corp | Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére |
EP3859425B1 (en) | 2015-09-17 | 2024-04-17 | S.D. Sight Diagnostics Ltd. | Methods and apparatus for detecting an entity in a bodily sample |
US10955423B2 (en) | 2015-12-15 | 2021-03-23 | The General Hospital Corporation | Methods of estimating blood glucose and related systems |
CA3018536A1 (en) | 2016-03-30 | 2017-10-05 | S.D. Sight Diagnostics Ltd | Distinguishing between blood sample components |
WO2017177192A1 (en) | 2016-04-07 | 2017-10-12 | The General Hospital Corporation | White blood cell population dynamics |
AU2017263807B2 (en) * | 2016-05-11 | 2023-02-02 | S.D. Sight Diagnostics Ltd | Performing optical measurements on a sample |
EP3455610B1 (en) | 2016-05-11 | 2023-01-04 | S.D. Sight Diagnostics Ltd. | Sample carrier for optical measurements |
EP3710810B1 (en) | 2017-11-14 | 2023-09-06 | S.D. Sight Diagnostics Ltd. | Sample carrier for optical measurements |
JPWO2022102734A1 (ja) * | 2020-11-13 | 2022-05-19 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02304354A (ja) * | 1989-05-18 | 1990-12-18 | Toa Medical Electronics Co Ltd | 血液データの解析方法 |
JPH11326315A (ja) * | 1998-05-21 | 1999-11-26 | Sysmex Corp | β−サラセミアの鑑別方法 |
JP2004510974A (ja) * | 2000-09-29 | 2004-04-08 | コールター インターナショナル コーポレイション | 異常な粒子集団を分析する為の方法 |
JP2007514955A (ja) * | 2003-12-19 | 2007-06-07 | ベックマン コールター,インコーポレイティド | 細胞1個ごとにヘモグロビンを測定するための改良された方法と装置 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2656508A (en) | 1949-08-27 | 1953-10-20 | Wallace H Coulter | Means for counting particles suspended in a fluid |
US3810011A (en) * | 1970-05-25 | 1974-05-07 | Coulter Electronics | Apparatus and method for analyzing the particle volume distribution for a plurality of particles of different size in a quantity of liquid |
JPS5916667B2 (ja) * | 1975-02-28 | 1984-04-17 | トウアイヨウデンシ カブシキガイシヤ | 自動血液分析装置 |
JPS5379599A (en) * | 1976-12-23 | 1978-07-14 | Toa Medical Electronics | Automatic blood analyzer |
US4521518A (en) * | 1980-06-16 | 1985-06-04 | Coulter Electronics, Inc. | Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes |
US4528274A (en) * | 1982-07-06 | 1985-07-09 | Coulter Electronics, Inc. | Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes |
KR970007077B1 (ko) | 1987-03-13 | 1997-05-02 | 코울터 일렉트로닉스 인커퍼레이티드 | 광산란 기술을 이용한 다중-부분식별 분석 방법 |
JP3703858B2 (ja) * | 1993-09-30 | 2005-10-05 | シスメックス株式会社 | 帰属度判別装置 |
AU1984295A (en) * | 1994-03-11 | 1995-09-25 | Abbott Laboratories | Cyanide-free reagent and method for the determination of hemoglobin |
US5834315A (en) | 1994-12-23 | 1998-11-10 | Coulter Corporation | Cyanide-free reagent and method for hemoglobin determination and leukocyte differentitation |
JP2000502446A (ja) * | 1995-12-18 | 2000-02-29 | センター フォー ラボラトリー テクノロジー,インク. | 血液診断装置及び判定方法 |
US5686309A (en) * | 1996-01-19 | 1997-11-11 | Coulter International Corp. | Method and apparatus for determination of hemoglobin content of individual red blood cells |
US5763280A (en) * | 1997-01-21 | 1998-06-09 | Coulter International Corp. | Cyanide-free lytic reagent composition and method for hemoglobin and cell analysis |
US5882934A (en) | 1997-01-21 | 1999-03-16 | Coulter International Corp. | Composition and method for hemoglobin and cell analysis |
US5935857A (en) * | 1997-08-01 | 1999-08-10 | Coulter International Corp. | Blood diluent |
US6030838A (en) * | 1998-09-24 | 2000-02-29 | Emt & Associates, Inc. | Hematological parameter |
US6228652B1 (en) * | 1999-02-16 | 2001-05-08 | Coulter International Corp. | Method and apparatus for analyzing cells in a whole blood sample |
US20020098589A1 (en) * | 2001-01-19 | 2002-07-25 | Crews Harold Richardson | Multi-purpose reagent system and method for enumeration of red blood cells, white blood cells and thrombocytes and differential determination of white blood cells |
US6268217B1 (en) * | 1999-11-12 | 2001-07-31 | James C. Barton | Erythrocyte parameters in hemochromatosis |
US20030027347A1 (en) * | 2001-05-25 | 2003-02-06 | Phyllis Shapiro | Automated method for correcting blood analysis parameter results affected by interference from exogenous blood substitutes in whole blood, plasma, and serum |
US6573102B2 (en) | 2001-07-27 | 2003-06-03 | Coulter International Corp. | Lytic reagent composition for determination of nucleated blood cells |
US7659074B2 (en) | 2001-09-14 | 2010-02-09 | Roche Diagnostics Corporation | Diagnosis and treatment of disorders of iron metabolism |
ES2297011T3 (es) * | 2001-09-14 | 2008-05-01 | F. Hoffmann-La Roche Ag | Diagnostico diferencial de los trastornos del metabolismo del hierro por medio de tres parametros independientes y recomendaciones para el tratamiento de estos trastornos del metabolismo del hierro. |
US6706526B2 (en) | 2002-01-24 | 2004-03-16 | Coulter International Corp. | Low formaldehyde producing blood diluent |
US6916662B2 (en) * | 2003-01-31 | 2005-07-12 | Abbott Laboratories | Performance improvement for hematology analysis |
US7586589B2 (en) * | 2005-09-24 | 2009-09-08 | Beckman Coulter, Inc. | Methods of determination of responsiveness to erythropoietin treatment |
US7609369B2 (en) * | 2005-09-24 | 2009-10-27 | Beckman Coulter, Inc. | Methods of detection of iron deficiency and hemochromatosis |
EP2016423B1 (en) * | 2006-01-20 | 2011-07-13 | Beckman Coulter, Inc. | Methods of detection of iron deficiency |
-
2007
- 2007-01-19 EP EP07717317A patent/EP2016423B1/en active Active
- 2007-01-19 JP JP2008551541A patent/JP4925364B2/ja active Active
- 2007-01-19 JP JP2008551542A patent/JP4822562B2/ja not_active Expired - Fee Related
- 2007-01-19 US US11/624,845 patent/US7361512B2/en active Active
- 2007-01-19 WO PCT/US2007/060753 patent/WO2007084977A2/en active Application Filing
- 2007-01-19 US US11/624,855 patent/US7361510B2/en active Active
- 2007-01-19 WO PCT/US2007/060752 patent/WO2007084976A2/en active Application Filing
- 2007-01-19 EP EP07710218A patent/EP1976541B1/en active Active
-
2011
- 2011-11-30 JP JP2011262741A patent/JP5592339B2/ja not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02304354A (ja) * | 1989-05-18 | 1990-12-18 | Toa Medical Electronics Co Ltd | 血液データの解析方法 |
JPH11326315A (ja) * | 1998-05-21 | 1999-11-26 | Sysmex Corp | β−サラセミアの鑑別方法 |
JP2004510974A (ja) * | 2000-09-29 | 2004-04-08 | コールター インターナショナル コーポレイション | 異常な粒子集団を分析する為の方法 |
JP2007514955A (ja) * | 2003-12-19 | 2007-06-07 | ベックマン コールター,インコーポレイティド | 細胞1個ごとにヘモグロビンを測定するための改良された方法と装置 |
Also Published As
Publication number | Publication date |
---|---|
JP2009524068A (ja) | 2009-06-25 |
EP1976541A4 (en) | 2010-03-03 |
EP2016423A2 (en) | 2009-01-21 |
US7361512B2 (en) | 2008-04-22 |
US7361510B2 (en) | 2008-04-22 |
JP4925364B2 (ja) | 2012-04-25 |
US20070172956A1 (en) | 2007-07-26 |
EP2016423B1 (en) | 2011-07-13 |
US20070172955A1 (en) | 2007-07-26 |
WO2007084976A2 (en) | 2007-07-26 |
WO2007084976A3 (en) | 2008-03-27 |
JP2009524069A (ja) | 2009-06-25 |
EP1976541A2 (en) | 2008-10-08 |
JP5592339B2 (ja) | 2014-09-17 |
JP2012042488A (ja) | 2012-03-01 |
WO2007084977A2 (en) | 2007-07-26 |
WO2007084977A3 (en) | 2007-11-29 |
EP2016423A4 (en) | 2010-03-03 |
EP1976541B1 (en) | 2011-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4822562B2 (ja) | 低ヘモグロビン濃度細胞百分率および鉄欠乏の検出における使用方法 | |
JP4743723B2 (ja) | 鉄欠乏およびヘモクロマトーシスの検出法 | |
Mast et al. | Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency | |
US8192995B2 (en) | Method of correction of particle interference to hemoglobin measurement | |
Mast et al. | Reticulocyte hemoglobin content | |
EP2202523B1 (en) | Diagnosis assisting system | |
EP1574839B1 (en) | Sample analyzer and computer program product | |
EP2524222B1 (en) | Determining volume and hemoglobin content of individual red blood cells | |
JP3523878B2 (ja) | ヘモグロビンの定量用無シアン化物試薬及び方法 | |
Fletcher et al. | Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children. | |
EP2982979B1 (en) | Method for evaluating urine sample, analyzer, and analysis system | |
JP2009510402A (ja) | エリスロポエチン治療に対する反応性の決定法 | |
Oyaert et al. | Estimated urinary osmolality based on combined urinalysis parameters: a critical evaluation | |
CA2345475A1 (en) | A new hematological parameter | |
Al-Fadhli et al. | Effect of sickle cell trait and ß-Thalassemia minor on determinations of HbA1c by an immunoassay method | |
Kelleher et al. | Haemoglobin, not haematocrit, should be the preferred parameter for the evaluation of anaemia in renal patients | |
Dedeene | CLINICAL/DIAGNOSTIC SCENARIO | |
Christensen et al. | New Erythrocyte Diagnostic Parameters in Neonatal Medicine | |
Urrechaga et al. | Triaging Microcytic Anemia using Extended RBC Parameters from Automated Hematology Analyzer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101111 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110830 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110902 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110905 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4822562 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140916 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |